DUBLIN, Ireland, July 13, 2026
Keenova Therapeutics plc has announced the publication of a new peer-reviewed real-world evidence study evaluating the use of Acthar® Gel (repository corticotropin injection) in patients with severe autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and dermatomyositis/polymyositis (DM/PM). Published in the Journal of Comparative Effectiveness Research, the retrospective physician-reported medical chart review provides important insights into patient characteristics, treatment patterns, and physician-assessed clinical outcomes among individuals receiving Acthar Gel, particularly those with complex disease who had limited responses to previous therapies. The publication expands the growing body of real-world clinical evidence supporting Acthar Gel in challenging autoimmune conditions and highlights its potential role as a therapeutic option for carefully selected patients with severe inflammatory diseases.
Real-World Evidence Expands Understanding of Acthar Gel
The newly published study analyzed physician-reported medical charts from patients diagnosed with RA, SLE, and DM/PM, focusing on treatment utilization and clinical outcomes observed in routine medical practice. Unlike controlled clinical trials, the research reflects real-world patient management, offering valuable information on how physicians are using Acthar Gel in individuals with severe autoimmune disorders that are often difficult to treat. According to the investigators, available real-world evidence for Acthar Gel in these diseases has historically been limited, making this publication an important contribution to understanding treatment decisions and patient management outside traditional clinical trial settings. The findings suggest that clinicians continue to consider Acthar Gel a meaningful therapeutic option for appropriate patients whose disease remains active despite previous treatment approaches.
Supporting Physicians Managing Complex Autoimmune Diseases
Autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and dermatomyositis/polymyositis are chronic inflammatory disorders that can significantly affect quality of life through persistent pain, organ involvement, muscle weakness, fatigue, and progressive disability. Many patients experience inadequate responses to conventional therapies, creating an ongoing need for additional treatment strategies. The published analysis provides physicians with further evidence regarding real-world prescribing patterns and physician-reported outcomes associated with Acthar Gel, helping inform treatment decisions for patients with severe or treatment-refractory disease. Company leaders noted that expanding clinical evidence remains essential for improving patient care and supporting informed therapeutic decision-making in complex autoimmune conditions.
Advertisement
Advancing Evidence-Based Autoimmune Treatment Research
The publication reflects Keenova Therapeutics’ continued commitment to strengthening the scientific evidence supporting its specialty therapeutics portfolio through observational research and real-world data generation. As healthcare systems increasingly incorporate real-world evidence into clinical practice and regulatory decision-making, studies such as this provide valuable complementary information alongside randomized clinical trials. While the company emphasized that treatment decisions should always be individualized according to approved prescribing information and physician judgment, the newly published research contributes additional evidence supporting Acthar Gel as a potential option for eligible patients with severe autoimmune diseases who have not responded adequately to previous therapies. By expanding the available evidence base, Keenova aims to support clinicians, researchers, and healthcare providers in optimizing care for patients living with chronic autoimmune disorders while continuing to advance innovation across multiple specialty therapeutic areas.
Source: Keenova Therapeutics press release
